WO2000067731A3 - Medicinal substance utilization for preventing nitrate tolerance - Google Patents

Medicinal substance utilization for preventing nitrate tolerance Download PDF

Info

Publication number
WO2000067731A3
WO2000067731A3 PCT/DE2000/001413 DE0001413W WO0067731A3 WO 2000067731 A3 WO2000067731 A3 WO 2000067731A3 DE 0001413 W DE0001413 W DE 0001413W WO 0067731 A3 WO0067731 A3 WO 0067731A3
Authority
WO
WIPO (PCT)
Prior art keywords
medicinal substance
nitrate tolerance
substance utilization
preventing
preventing nitrate
Prior art date
Application number
PCT/DE2000/001413
Other languages
German (de)
French (fr)
Other versions
WO2000067731A2 (en
Inventor
Michael Stoeter
Gerd Koenig
Eberhard Bassenge
Original Assignee
Alpharma Gmbh & Co Kg
Michael Stoeter
Gerd Koenig
Eberhard Bassenge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpharma Gmbh & Co Kg, Michael Stoeter, Gerd Koenig, Eberhard Bassenge filed Critical Alpharma Gmbh & Co Kg
Priority to AU58020/00A priority Critical patent/AU5802000A/en
Priority to EP00943550A priority patent/EP1173214A2/en
Publication of WO2000067731A2 publication Critical patent/WO2000067731A2/en
Publication of WO2000067731A3 publication Critical patent/WO2000067731A3/en
Priority to BG105955A priority patent/BG105955A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention describes the utilization of medicinal substances for preventing nitrate and/or nitrate cross-tolerance and pathological phenomena accompanying the latter.
PCT/DE2000/001413 1999-05-05 2000-05-05 Medicinal substance utilization for preventing nitrate tolerance WO2000067731A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU58020/00A AU5802000A (en) 1999-05-05 2000-05-05 Medicinal substance utilization for preventing nitrate tolerance
EP00943550A EP1173214A2 (en) 1999-05-05 2000-05-05 Medicinal substance utilization for preventing nitrate tolerance
BG105955A BG105955A (en) 1999-05-05 2001-09-26 Medicinal substance utilization for preventing nitrate tolerance

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19920775A DE19920775A1 (en) 1999-05-05 1999-05-05 Use of drugs to avoid nitrate tolerance
DE19920775.5 1999-05-05

Publications (2)

Publication Number Publication Date
WO2000067731A2 WO2000067731A2 (en) 2000-11-16
WO2000067731A3 true WO2000067731A3 (en) 2001-01-25

Family

ID=7907118

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2000/001413 WO2000067731A2 (en) 1999-05-05 2000-05-05 Medicinal substance utilization for preventing nitrate tolerance

Country Status (6)

Country Link
EP (1) EP1173214A2 (en)
AU (1) AU5802000A (en)
BG (1) BG105955A (en)
DE (1) DE19920775A1 (en)
PL (1) PL352024A1 (en)
WO (1) WO2000067731A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537992B2 (en) 2001-01-05 2003-03-25 John D. Parker Regulation of organic nitrate tolerance
GB0909243D0 (en) * 2009-05-29 2009-07-15 Univ Dundee Angina treatment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3839826A1 (en) * 1988-11-25 1990-05-31 Henning Berlin Gmbh ALKALI AND EARTH ALKALINE SALTS OF OXIPURINOL IN AMORPHER OR CRYSTALLINE FORM AS A MEDICINE FOR TREATING HYPERURICAEMIA AND Gout

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C.G.SOBEY E.A.: "Allopurinol and amlodipine improve coronary vasodilatation after myocardial ischaemia and reperfusion in anaesthetized dogs", BRITISH JOURNAL OF PHARMACOLOGY, vol. 108, no. 2, 1993, pages 342 - 347, XP000953125 *
T.M.MILLAR E.A.: "Xanthine oxidoreductase catalyses the reduction of nitrates and nitrite to nitric oxide under hypoxic conditions", FEBS LETTERS, vol. 427, 1998, pages 225 - 228, XP002133526 *

Also Published As

Publication number Publication date
EP1173214A2 (en) 2002-01-23
DE19920775A1 (en) 2000-11-16
AU5802000A (en) 2000-11-21
BG105955A (en) 2002-06-28
PL352024A1 (en) 2003-07-14
WO2000067731A2 (en) 2000-11-16

Similar Documents

Publication Publication Date Title
IL132426A0 (en) An amyloid binding compound and pharmaceutical compositions containing the same
AU7419900A (en) Substance library containing bicyclic imidazo-5-yl-amines and/or bicyclic imidazo-3-yl-amines
AU4818099A (en) Phosphodiesterase-v modulator drugs and their uses
BR9713237B1 (en) Alfuzosine hydrochloride controlled release tablet and pharmaceutical composition comprising the same.
IS5885A (en) Oral administration system which provides time and space control over the administration
AU3813499A (en) The use of dihydropyrimidines as medicaments, and novel substances
IL135646A0 (en) α-ARYL-N-ALKYLNITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
AU3460297A (en) Taxane derivatives and drugs containing the same
ZA971869B (en) Implants with phasewise release of pharmaceutical substance.
ZA200104280B (en) Pharmaceutical combination preparations.
HUP0201952A2 (en) Androgen compounds and pharmaceutical compounds containing the same
AU5880498A (en) New benzolactam derivatives and medicinal compositions containing the same
AU2001269474A1 (en) Phenylpyridazine Compounds and Medicines Containing the Same
AU1509999A (en) Herbal drug composition for the prevention and treatment of dementia
GB2346863B (en) Assembly system and lowerator therefor
AU3866897A (en) Diamide compounds and drugs containing the same
NO20004600D0 (en) Foodstuffs and processes for making the same
ZA200109989B (en) Pharmaceutical composition containing sibutramine and orlistat.
AU6119398A (en) Phenylpropenone compounds and medicines containing the same
WO2000067731A3 (en) Medicinal substance utilization for preventing nitrate tolerance
AU2001274535A1 (en) Hydroxyformamidine derivatives and medicines containing the same
AU1186300A (en) Drugs and reagents containing n-acyloxylated cycloalkyl compounds as the active ingredient
WO1999033451A3 (en) Mixture and pharmaceutical composition comprising z-4-hydroxytamoxifen and cyclodextrin
IL129574A0 (en) Benzenesulfonamide derivatives and drugs containing the same
AU8095598A (en) Hair-drier or the like

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AU BA BB BG BR BY CA CN CR CU CZ DE DM EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX NO NZ PL RO RU SG SI SK TR TT TZ UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AU BA BB BG BR BY CA CN CR CU CZ DE DM EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX NO NZ PL RO RU SG SI SK TR TT TZ UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000943550

Country of ref document: EP

ENP Entry into the national phase

Ref country code: BG

Ref document number: 2000 105955

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PV2001-3926

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2000943550

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000943550

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2001-3926

Country of ref document: CZ

NENP Non-entry into the national phase

Ref country code: JP